7 Pfizer COVID-19 Trade Secrets in 3.2.P.1?

There appear to be up to 7 fully redacted ingredients in Pfizer’s experimental genetic vaccine BNT162b2. In this video, I discuss a heavily redacted excerpt of Section 3.2.P.1 from a confidential Pfizer document, released by the MHRA in response to my Freedom of Information request. For further details, please visit alltherisks.com/trade-secret. I have already extensively documented #AllTheRisks across toxicology, molecular biology, virology, immunology and epidemiology in a fully independent biosecurity risk assessment at http://www.alltherisks.com.

Summary Basis for Regulatory Action – Comiranty

Source: https://www.fda.gov/media/151733/download


CRITICAL UPDATE! In response to my Freedom of Information (FOI) request, on 11 November 2021, the MHRA provided the below heavily redacted excerpt from a confidential Pfizer document. Table 3.2.P.1-1 appears to list 7 fully redacted ingredients.

Background: COMIRNATY is a trade name of Pfizer’s experimental SARS-CoV-2 genetic vaccine BNT162b2, the same experimental product deployed in the UK under Regulation 174 from the MHRA, the UK’s Medicines and Healthcare Regulatory Agency. According to the CDC, “There has been no change in the formulation of the vaccine since the name change.” The FDA’s document Summary Basis for Regulatory Action – COMIRNATY, dated 23 August 2021, outlined the full approval of COMIRNATY. As below, Table 2 protected a 0.450ml excipient from public disclosure, according to U.S.C. § 552(b)(4), in lieu of “[t]rade secrets and commercial or financial information obtained from a person and privileged or confidential”.

Without reversioning their document, as below, the FDA later spontaneously updated Table 2 to supposedly reveal this previously undisclosed excipient to simply be water for injection (UNII: 059QF0KO0R).

However, this new disclosure cannot be reconciled with Table 3 in the same FDA document.

Therefore, on 20 October 2021, I raised a Freedom of Information (FOI) request to the MHRA entitled: Exact quantity of Water for Injection pre and post dilution in BNT162b2.

On 28 October 2021, the MHRA responded with the following:

The duty in Section 1(1)(a) of the Freedom of Information (FOI) Act 2000 does not apply, by virtue of Section 41 (Information provided in confidence) and Section 43 (Commercial interests) of that Act.

Section 41 is an absolute exemption and no consideration of the public interest is required, except to state that we consider its disclosure to constitute an actionable breach of confidence.

Section 43 is a qualified exemption and a consideration of the public interest should be made. We have considered the public interest and cannot see any public interest argument that outweighs the commercial harm whereby the information can be used by competitors to inform their own product development and overcome regulatory hurdles.

Critical questions that must immediately be addressed by the MHRA therefore include:

  1. What could possibly warrant the MHRA’s decision to not disclose the exact amount of water for injection (UNII: 059QF0KO0R) in BNT162b2 by invoking an absolute exemption (Section 41) and a qualified exemption (Section 43)?
  2. Why would the disclosure of the exact amount of water for injection (UNII: 059QF0KO0R) in BNT162b2 inflict any “commercial harm” on Pfizer, as the MHRA claim?
  3. If the only solution present in BNT162b2 in liquid or frozen state is water for injection (UNII: 059QF0KO0R) then how could confirmation that it comprises the entire solution of BNT162b2 in its pre-dilution and post-dilution state “be used by competitors to inform their own product development and overcome regulatory hurdles”?

A diagram of mine illustrating dilution and post-dilution dosing of BNT162b2 is shown below.

DoD Cloud Strategy

Source: https://media.defense.gov/2019/Feb/04/2002085866/-1/-1/1/DOD-CLOUD-STRATEGY.PDF

Strategic Environment
“If we fail to adapt … at the speed of relevance, then our military forces … will lose the
very technical and tactical advantages we’ve enjoyed since World War II “

  • Secretary of Defense James N Mattis
    Information is vital to United States (U.S.) national security and our ability to understand
    emerging threats, project power globally, conduct operations, support diplomatic efforts, and
    enable global economic viability. The Department of Defense (DoD) has multiple disjointed and
    stove-piped information systems distributed across modem and legacy infrastructure around the
    globe leading to a litany of problems that impact warfighters’, decision makers’, and DoD staffs
    ability to organize, analyze, secure, scale, and ultimately, capitalize on critical information to make
    timely, data-driven decisions. Today, the Department is largely constrained by physical resources,
    manpower limitations, organic skillsets and, oftentimes, laborious contracting processes to procure
    or grow storage and computing capabilities. In addition, the cyberspace domain continues to be an
    increasingly contested environment. In order for the U.S. to keep its strategic advantage,
    warfighters and the force that support them need to be provided with the proper capabilities and
    technologies to succeed.
    To this end, commercial industry has made significant strides in addressing these
    challenges that the Department can leverage. Commercial cloud computing is a subscription-based
    service that provides network-based storage and compute resources. It allows users to store and
    access data and programs over the Internet rather than on a local computer hard drive. It also allows
    users to access information from anywhere at any time, effectively removing the need for the user
    to be in the same physical location as the hardware that stores the data. The Department must take
    full advantage of this technology enabler.

The Gateway Pundit – WONDER DRUG: New International Ivermectin Report of 64 Studies Shows 86% Success as Prophylaxis and 67% Success in Early Treatment

By Jim Hoft

Source: https://www.thegatewaypundit.com/2021/11/wonder-drug-new-international-ivermectin-report-64-studies-shows-86-success-prophylaxis-67-success-early-treatment/

PDF source for Ivermectin for COVID-19 real time meta analysis of 65 studies: https://ivmmeta.com/ivm-meta.pdf

Covid studies for hydroxychloroquine : https://c19hcq.com/

A new international report of 64 studies shows Ivermectin has an 86% success rate as a prphylaxis and a 67% success rate in early treatment of coronavirus.

The results mirror the over 290 studies on hydroxychloroquine that have been reported over the past year.

The CDC, Dr. Fauci and the FDA ridiculed the use of the drugs to treat the China Virus despite their continued effectiveness in peer reviewed studies. At some point they are going to have to put their pride aside and admit they were wrong and the likely cause of millions of deaths from the deadly virus.


Obama Science Advisor Called For Planetary Regime To Enforce Totalitarian Population Control Measures
In 1977 book, John Holdren advocated forced abortions, mass sterilization through food and water supply and mandatory bodily implants to prevent pregnancies

”’John Paul Holdren”’ (born March 1, 1944) was the senior advisor to President Barack Obama on science and technology issues through his roles as Assistant to the President for Science and Technology, Director of the White House Office of Science and Technology Policy, and Co-Chair of the United States President’s Council of Advisors on Science and Technology|President’s Council of Advisors on Science and Technology (PCAST). Holdren was previously the Teresa and John Heinz Professor of Environmental Policy at the Kennedy School of Government at Harvard University, director of the Science, Technology, and Public Policy Program at the School’s Belfer Center for Science and International Affairs, and Director of the Woods Hole Research Center.News release. [http://www.aaas.org/news/releases/2008/1218holdren.shtml “Obama to Name John P. Holdren as Science Adviser”] AAAS, December 18, 2008.

Agenda 21 – United Nations Conference on Environment & Development
Rio de Janerio, Brazil, 3 to 14 June 1992


Microsoft Attention Spans Research Report

Attention spans – Consumer Insights, Microsoft Canada

The average human attention span in 2013 is 9 seconds